Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

810.05INR
23 Oct 2014
Price Change (% chg)

Rs3.80 (+0.47%)
Prev Close
Rs806.25
Open
Rs811.00
Day's High
Rs812.40
Day's Low
Rs808.80
Volume
172,296
Avg. Vol
2,301,591
52-wk High
Rs878.40
52-wk Low
Rs552.55

SUN.NS

Chart for SUN.NS

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.62
Market Cap (Mil.): Rs1,677,746.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.19

Financials

  SUN.NS Industry Sector
P/E (TTM): 28.53 33.08 33.86
EPS (TTM): 28.39 -- --
ROI: -- 18.26 17.53
ROE: -- 18.93 18.34
Search Stocks

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI, Sept 4 - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India's Ranbaxy Laboratories posts loss in June quarter

MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.

29 Jul 2014

India's Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

15 Jul 2014

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

27 Jun 2014

UPDATE 1-India's Ranbaxy posts loss after write-offs on US import bans

* Compares with analysts' forecast for 958.7 mln in profit

09 May 2014

India's Ranbaxy posts March-quarter loss on write-offs

MUMBAI, May 9 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by rival Sun Pharmaceutical Industries Ltd for $3.2 billion, posted a surprise loss in the March quarter due to write-offs related to regulatory sanctions for poor manufacturing quality.

09 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks